EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target

Michel A Struwe, Axel J Scheidig, Bernd Clement

Journal of Biological Chemistry · 2023-11 · 299 (11) · 105306

DOI: 10.1016/j.jbc.2023.105306 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Biological Chemistry, 2023-11. Verfasst von Michel A Struwe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Zoologisches Institut - Strukturbiologie, Christian-Albrechts-Universität Kiel, Kiel, Germany; Pharmazeutisches Institut, Christian-Albrechts-Univers…. Hauptthemen laut MEDLINE: Oxidoreductases, Prodrugs. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joachim Herz Stiftung, Studienstiftung des Deutschen Volkes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitochondrial amidoxime-reducing component (mARC) is one of five known molybdenum enzymes in eukaryotes. mARC belongs to the MOSC domain superfamily, a large group of so far poorly studied molybdoenzymes. mARC was initially discovered as the enzyme activating N-hydroxylated prodrugs of basic amidines but has since been shown to also reduce a variety of other N-oxygenated compounds, for example, toxic nucleobase analogs. Under certain circumstances, mARC might also be involved in reductive nitric oxide synthesis through reduction of nitrite. Recently, mARC enzymes have received a lot of attention due to their apparent involvement in lipid metabolism and, in particular, because many genome-wide association studies have shown a common variant of human mARC1 to have a protective effect against liver disease. The mechanism linking mARC enzymes with lipid metabolism remains unknown. Here, we give a comprehensive overview of what is currently known about mARC enzymes, their substrates, structure, and apparent involvement in human disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxidoreductasesProdrugsHumansGenome-Wide Association StudyOxidation-ReductionAnimalsOximes

Stichwörter der Autor:innen

drug metabolismenzymelivermARCmetalloproteinmolybdenumnitric oxide

Substanzen

OxidoreductasesProdrugsamidoximeOximes

Autor:innen und Institutionen

  • Zoologisches Institut - Strukturbiologie, Christian-Albrechts-Universität Kiel, Kiel, Germany; Pharmazeutisches Institut, Christian-Albrechts-Universität Kiel, Kiel, Germany. Electronic address: mstruwe@strubio.uni-kiel…
  • Zoologisches Institut - Strukturbiologie, Christian-Albrechts-Universität Kiel, Kiel, Germany.
  • Pharmazeutisches Institut, Christian-Albrechts-Universität Kiel, Kiel, Germany.

Förderung

  • Joachim Herz Stiftung
  • Studienstiftung des Deutschen Volkes

Zitieren

APA

Struwe, M. A., Scheidig, A. J., & Clement, B. (2023). The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target. Journal of Biological Chemistry, 299(11), 105306. https://doi.org/10.1016/j.jbc.2023.105306

Vancouver

Struwe MA, Scheidig AJ, Clement B. The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target. Journal of Biological Chemistry. 2023;299(11):105306. doi:10.1016/j.jbc.2023.105306

BibTeX
@article{Struwe2023,
  author = {Struwe, Michel A and Scheidig, Axel J and Clement, Bernd},
  title = {The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  volume = {299},
  number = {11},
  pages = {105306},
  doi = {10.1016/j.jbc.2023.105306}
}
Kostenlos starten →